SCYNEXIS, Inc. (SCYX)
| Market Cap | 37.66M +15.2% |
| Revenue (ttm) | 19.22M +490.0% |
| Net Income | -10.24M |
| EPS | -1.33 |
| Shares Out | 9.95M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 54,997 |
| Open | 3.800 |
| Previous Close | 3.810 |
| Day's Range | 3.710 - 3.840 |
| 52-Week Range | 3.530 - 9.120 |
| Beta | 1.06 |
| Analysts | Strong Buy |
| Price Target | 36.33 (+859.84%) |
| Est. Earnings | Nov 9, 2026 |
About SCYX
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in... [Read more]
Financial Performance
In 2025, SCYNEXIS's revenue was $20.60 million, an increase of 449.95% compared to the previous year's $3.75 million. Losses were -$8.61 million, -59.56% less than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for SCYX stock is "Strong Buy." The 12-month stock price target is $36.33, which is an increase of 859.84% from the latest price.
News
Scynexis announces topline results from SCY-247 trial
Scynexis (SCYX) announced topline results from its Phase 1 single ascending dose, or SAD, and multiple ascending dose, or MAD, trial of the intravenous, or IV, formulation of SCY-247, its…
SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases
JERSEY CITY, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”, or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions fo...
SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek
JERSEY CITY, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for...
SCYNEXIS Slides: Corporate presentation
SCYNEXIS has posted slides in relation to its latest quarterly earnings report, which was published on October 21, 2026.
Scynexis completes study of SCY-770
Scynexis (SCYX) announced completion of a Phase 1 study of SCY-770, a selective and direct AMP-activated protein kinase activator. The study was conducted to evaluate the safety and tolerability, as…
SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• SCY-770 was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated
Brookline says BARDA contract a major positive for Scynexis’ SCY-247 program
Brookline analyst Kemp Dolliver reiterates a Buy rating on Scynexis (SCYX) with a price target of $44 as the firm believes the award of a contract by the Biomedical Advanced…
Scynexis awarded contract by BARDA contract, providing up to $214M in funding
Scynexis (SCYX) announced that it has been awarded a contract by the Biomedical Advanced Research and Development Authority, BARDA, part of the Administration for Strategic Preparedness and Response, ...
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
JERSEY CITY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions fo...
Scynexis appoints Burke to Board of Directors
Scynexis (SCYX) announced the appointment of Steven Burke, M.D., to its Board of Directors, effective September 18, 2026. Burke worked at Akebia Therapeutics (AKBA) since 2019.
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D.
JERSEY CITY, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions fo...
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
JERSEY CITY, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (the Company or SCYNEXIS), a clinical-stage biotechnology company dedicated to advancing innovative solutions for se...
SCYNEXIS Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The company is advancing two orphan disease programs, highlighted by the recent acquisition of SCY-770 for ADPKD. Key milestones include phase I study completions and a phase II trial set to start by year-end, with interim efficacy data expected next year. SCY-770’s mechanism and preclinical data support its potential in a market with high unmet need.
Scynexis CFO Ivor Macleod retires, Sanjay Subramanian succeeds
Scynexis (SCYX) announced the appointment of Sanjay Subramanian as CFO, effective September 9. The company also announced the retirement of Ivor Macleod from his role as CFO, effective September 9,…
SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
Accomplished biopharmaceutical finance executive brings extensive experience driving capital markets activities, strategic transactions, and growth across public companies Accomplished biopharmaceutic...
SCYNEXIS to Participate in Upcoming Investor Conferences
JERSEY CITY, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat...
SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
JERSEY CITY, N.J., Aug. 25, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX), a clinical-stage biotechnology company focused on developing innovative therapies for severe and difficult-to-treat ...
Scynexis price target raised to $33 from $24 at Guggenheim
Guggenheim raised the firm’s price target on Scynexis (SCYX) to $33 from $24 and keeps a Buy rating on the shares to account for quarterly results and the inclusion of…
Scynexis reports Q2 EPS 63c, consensus (51c)
Reports Q2 revenue $235,000, consensus $80,330. “The initiation of our Phase 1 study marks an important milestone in the advancement of SCY-770 and our commitment to developing a potentially transform...
SCYNEXIS Quarterly report: Q2 2026
SCYNEXIS has published its Q2 2026 quarterly earnings report on August 10, 2026.
SCYNEXIS Earnings release: Q2 2026
SCYNEXIS released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Scynexis initiates SCY-770 study
Scynexis (SCYX) announced initiation of a Phase 1 study of SCY-770, an AMP-activated protein kinase activator. The study will characterize the food-effect and define the pharmacokinetics of two dosing...
SCYNEXIS Initiates Phase 1 Study of SCY-770, a Novel AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
JERSEY CITY, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company advancing novel therapies for severe rare diseases, today announced initiatio...
SCYNEXIS Transcript: AGM 2026
The meeting established a quorum and proceeded with six proposals, including director elections, auditor ratification, and amendments to the equity plan and certificate of incorporation. All proposals were approved, and no shareholder questions were submitted.
Scynexis trading halted, news pending
19:50 EDT Scynexis (SCYX) trading halted, news pending